Literature DB >> 8141213

Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation.

S A Friedman1, C J de Groot, R N Taylor, B D Golditch, J M Roberts.   

Abstract

OBJECTIVE: Our purpose was to determine the presence and degree of endothelial injury, by measuring plasma concentrations of cellular fibronectin, in pregnancies complicated by preeclampsia or intrauterine growth retardation. STUDY
DESIGN: A matched, nested, case-control study design was used. Plasma was collected prospectively from pregnant women throughout gestation. At least 12 weeks after delivery women with preeclampsia, both preeclampsia and intrauterine growth retardation, or intrauterine growth retardation alone were identified. Normal controls were matched to these patients by age, race, and gestational age. Stored plasma, which had been obtained in the third trimester, was assayed for cellular fibronectin by means of a sensitive and specific enzyme immunoassay. After an appropriate transformation of the data results were compared with one-way analysis of variance with Fisher's post hoc test.
RESULTS: Patients with preeclampsia (n = 18) had higher plasma cellular fibronectin concentrations than did control patients (n = 68) with median values of 2.8 and 1.4 micrograms/ml, respectively (p < 0.001, using transformed data). Patients with intrauterine growth retardation alone (n = 10) had 2.3 micrograms/ml cellular fibronectin, significantly higher than values of controls (p < 0.02 using transformed data) and significantly lower than those of patients with preeclampsia (p < 0.05 using transformed data).
CONCLUSION: Pregnancies complicated by preeclampsia had significantly higher plasma cellular fibronectin concentrations than did pregnancies with intrauterine growth retardation alone, which in turn had significantly higher plasma cellular fibronectin concentrations than did control pregnancies. We speculate that endothelial involvement in intrauterine growth retardation is confined to the uteroplacental circulation, whereas it is systemic in preeclampsia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8141213     DOI: 10.1016/s0002-9378(94)70295-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

Review 1.  Pathophysiology and maternal biologic markers of preeclampsia.

Authors:  Jacques Massé; Yves Giguère; Abdelaziz Kharfi; Joël Girouard; Jean-Claude Forest
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome.

Authors:  Robert W Powers; Janet M Catov; Lisa M Bodnar; Marcia J Gallaher; Kristine Y Lain; James M Roberts
Journal:  Reprod Sci       Date:  2008-01-09       Impact factor: 3.060

3.  Giants in Obstetrics and Gynecology Series: A profile of James M. Roberts, MD.

Authors:  Roberto Romero
Journal:  Am J Obstet Gynecol       Date:  2019-06       Impact factor: 8.661

4.  Maternal levels of prostacyclin, thromboxane, ICAM, and VCAM in normal and preeclamptic pregnancies.

Authors:  David F Lewis; Bernard J Canzoneri; Yang Gu; Shuang Zhao; Yuping Wang
Journal:  Am J Reprod Immunol       Date:  2010-12       Impact factor: 3.886

5.  The profiles of soluble adhesion molecules in the "great obstetrical syndromes".

Authors:  Nikolina Docheva; Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Gaurav Bhatti; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Tinnakorn Chaiworapongsa; Eli Maymon; Sonia S Hassan; Offer Erez
Journal:  J Matern Fetal Neonatal Med       Date:  2018-02-01

6.  The predictive value of plasma fibronectin concentration on fetal growth retardation at earlier stage of the third trimester.

Authors:  Z Wang; G Xiong; Y Zhu
Journal:  J Tongji Med Univ       Date:  2001

7.  Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?

Authors:  Shali Mazaki-Tovi; Roberto Romero; Sun Kwon Kim; Edi Vaisbuch; Juan Pedro Kusanovic; Offer Erez; Tinnakorn Chaiworapongsa; Francesca Gotsch; Pooja Mittal; Chia-Ling Nhan-Chang; Nandor Gabor Than; Ricardo Gomez; Jyh Kae Nien; Samuel S Edwin; Percy Pacora; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-08

8.  The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.

Authors:  Tinnakorn Chaiworapongsa; Jimmy Espinoza; Francesca Gotsch; Yeon Mee Kim; Gi Jin Kim; Luis F Goncalves; Samuel Edwin; Juan Pedro Kusanovic; Offer Erez; Nandor Gabor Than; Sonia S Hassan; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

9.  Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Francesca Gotsch; Jimmy Espinoza; Jyh Kae Nien; Luis Goncalves; Samuel Edwin; Yeon Mee Kim; Offer Erez; Juan Pedro Kusanovic; Beth L Pineles; Zoltan Papp; Sonia Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2008-01

10.  Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia.

Authors:  Giovanna Oggé; Roberto Romero; Tinnakorn Chaiworapongsa; Maria Teresa Gervasi; Percy Pacora; Offer Erez; Juan Pedro Kusanovic; Edi Vaisbuch; Shali Mazaki-Tovi; Francesca Gotsch; Pooja Mittal; Yeon Mee Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2010-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.